Key facts
- This page summarizes Anna Protopapas's Form 4 filing for Mersana Therapeutics, Inc. (MRSN).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 17 Jan 2025, 19:26.
Anna Protopapas - 15 Jan 2025 Form 4 Insider Report for Mersana Therapeutics, Inc. (MRSN)
- Reporting relationship
- Director
- Issuer ticker
- MRSN
- Reported as of
- 15 Jan 2025
- Net transaction value
- -$5,009
- SEC form
- 4
- Accepted by SEC
- 17 Jan 2025, 19:26:45 UTC
- Prior SEC filing
- 16 Jan 2025
- Next SEC filing
- 13 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Alejandra Carvajal, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Anna Protopapas filed Form 4 for Mersana Therapeutics, Inc. (MRSN) on 17 Jan 2025.
Change
- Previous filing in this sequence was filed on 16 Jan 2025.
- Current net transaction value: -$5,009.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRSN
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +21,250
- Change %
- +14%
- Price
- $0.000000
- Shares after
- 176,678
- Date
- 15 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
MRSN
transaction
Common Stock
Sale
- Transaction value
- $5,009
- Shares
- -8,637
- Change %
- -4.9%
- Price
- $0.5800
- Shares after
- 168,041
- Date
- 16 Jan 2025
- Ownership
- Direct
- Footnotes
- F2, F3
MRSN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 240,244
- Date
- 15 Jan 2025
- Ownership
- By Trust
- Footnotes
- F4
MRSN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 72,263
- Date
- 15 Jan 2025
- Ownership
- By Trust
- Footnotes
- F5
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRSN
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -21,250
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 15 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 21,250
- Exercise price
- Footnotes
- F6, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 7 footnotes
Footnote F1
Represents shares of common stock received upon vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person, who previously served as the Issuer's President and Chief Executive Officer, on January 15, 2021.
Footnote F2
Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 11, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person.
Footnote F3
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.56 to $0.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Footnote F4
These shares of common stock are held by the Anna Protopapas Irrevocable Trust (the "Protopapas Trust") for the benefit of the Reporting Person's spouse and children. The Reporting Person's spouse is the trustee of the Protopapas Trust.
Footnote F5
These shares of common stock are held by the Kinney/Protopapas Family Irrevocable Trust (the "Kinney/Protopapas Trust") for the benefit of the Reporting Person's children. The Reporting Person's spouse is a co-trustee of the Kinney/Protopapas Trust.
Footnote F6
Each RSU represents the contingent right to receive one share of common stock of the Issuer.
Footnote F7
Fully vested as of January 15, 2025.